Notably, a monoclonal antibody directed against the IL-4 receptor α subunit, blocking IL-4 and IL-13 signaling, has been evaluated in patients with atopic dermatitis, with significant improvement in disease severity (61). The gene discussed is IL13; the disease is atopic eczema.